Bank Of Nova Scotia Exelixis, Inc. Transaction History

Bank Of Nova Scotia

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$15.68 - $22.27 $11.6 Million - $16.5 Million	-740,510 Reduced 94.42%	43,757 $686,000
Q2 2022 Aug 08, 2022	BUY	$17.44 - $23.16 $13.7 Million - $18.2 Million	784,267 New	784,267 $16.3 Million
Q2 2022 Aug 05, 2022	SELL	$17.44 - $23.16 $608,324 - $807,843	-34,881 Closed	0 $0
Q1 2022 May 09, 2022	SELL	$17.03 - $22.67 $313,317 - $417,082	-18,398 Reduced 34.53%	34,881 $791,000
Q4 2021 Feb 11, 2022	BUY	$15.84 - $21.88 $445,341 - $615,156	28,115 Added 111.73%	53,279 $974,000
Q3 2021 Nov 12, 2021	BUY	$16.3 - $21.14 $62,070 - $80,501	3,808 Added 17.83%	25,164 $532,000
Q2 2021 Aug 12, 2021	BUY	$17.95 - $25.56 $383,340 - $545,859	21,356 New	21,356 $389,000

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Bank Of Nova Scotia, based on Form 13F filings with the SEC.

Stay updated on Bank Of Nova Scotia with notifications on news.